The conjugated complex has 1. Core Scaffold (R) – Polyol / Polythiol / Polyamine Backbone (Eg: pentaerythritol, glycerol, trimethylolpropane, polyglycerols) 2. Linker Atom (Oxygen (O), Sulfur (S), Nitrogen (–NH–)) 3. Polymer Arms (Polyethylene glycol 2,000–150,000 Da) 4. Linkage‑Containing Spacer (Xᵣ) 5. API

Not provided

Rezpegaldesleukin (NKTR-358; REZPEG) is a polyethylene glycol–conjugated recombinant human interleukin-2 (rhIL-2). Phase 2 results show Treatment-emergent adverse events (TEAEs) were reported in 66.0% of subjects receiving REZPEG compared with 48.7% of those receiving placebo, while treatment-related adverse events (TRAEs) occurred in 41.9% and 10.4% of subjects, respectively. Severe TEAEs were reported in 3.2% of subjects in the REZPEG group and 4.5% in the placebo group. The most frequently reported TRAE with REZPEG was injection-site reaction (ISR), occurring in 26.4% of subjects.

Not provided

Not provided

Not provided

Not provided

1. Reaction Vessels/bioreactors 2. Magnetic stirrers 3. Heating plates / heating mantles 4. Cooling baths (20°C, 50°C, 60°C operations described) 5. Temperature controllers / thermometers 6. Hand‑swirling for dissolution 7. Nitrogen/argon inert atmosphere setups (implied by anhydrous conditions) 8. Filtration apparatus (frit funnels, Büchner funnels) 9. Vacuum filtration setups 10. High‑vacuum drying systems (overnight drying)

To manufacture multi-arm conjugated complex, we need ISO cleanroom (class not explicited mentioned). Step1: Derive polymer from Lactide, Glycolide, Caprolactone or Combinations thereof (copolymers) Step 2: Ring-opening polymerization - initiated by alcohol-based initiators, using metal-based catalysts (e.g., tin-based catalysts) Step 3: Polymer purification, Removal of unreacted monomer, Drying of the polymer prior to formulation use Step 4: API and Polymer complex formation using Melt or semi-solid processing or solvent based mixing.

1. 500 MHz Bruker ¹H NMR spectrometer Drug content & release: 2. HPLC or UPLC 3. UV–Vis spectroscopy Polymer–drug interaction: 4. DSC (thermal behavior) 5. FTIR (compatibility assessment) Physical characterization: 6. Particle size analyzers (if particulate) 7. Microscopy (optical / SEM implied) Stability & performance: 8. Dissolution or release testing apparatus 9. Accelerated stability chambers

Not provided

1. Carbohydrates (Monosaccharides; Disaccharides; Polysaccharides; Sugar alcohols (Alditols)) 2. Inorganic Salts (NaCl; KCl; NaSO4; KNO3; Na2PO3/Na2PO4) 3. Antimicrobial Agents (Benzalkonium chloride, Benzethonium chloride, Benzyl alcohol) 4. Antioxidants (Butylated hydroxyanisole (BHA)) 5. Surfactants (Polysorbates, Pluronics) 6. Buffers (Phosphate buffers) 7. Acids (HCL. HPO3, Acetic acid and citric acid) 8. Bases (NaOH, KOH, NH3OH)

Not provided

No delivery device

• Biodegradable

The release kinetics of the active pharmaceutical ingredient (API) are influenced by multiple factors, including the chemical stability of the linker (with ester < carbonate < carbamate < amide), local pH conditions, and the presence and activity of relevant enzymes (e.g., esterases and proteases). Additional determinants include PEG arm length and molecular architecture, as well as the degree of drug loading, defined by the number of conjugated arms.

This technology is adminstered as intratumoral injection. Intratumoral administration is conducted using a fine-gauge needle (approximately 22–25 gauge), with needle insertion angle and depth selected based on tumor size, location, and imaging guidance, where applicable.

- In situ stability: The stability of the conjugate in circulation is influenced by linker chemistry. Stable linkers (e.g., amides, thioethers) are resistant to hydrolytic cleavage under physiological conditions, whereas releasable linkers undergo gradual cleavage in biological environments. PEG chains (e.g., PEG 20 kDa) enhance aqueous solubility and reduce the risk of drug precipitation. -Formulation stability: Long-term stability studies are typically conducted under controlled conditions (25 °C ± 2 °C / 60% RH ± 5% RH). but no results were disclosed.

1. Refrigeration at 2–8 °C (most PEGylated cytokines) 2. Temperature‑controlled shipping